<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Quanterix Corp — News on 6ix</title>
<link>https://6ix.com/company/quanterix-corp</link>
<description>Latest news and press releases for Quanterix Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 12:33:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/quanterix-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b4ca78dffbe2df1134f0.webp</url>
<title>Quanterix Corp</title>
<link>https://6ix.com/company/quanterix-corp</link>
</image>
<item>
<title>Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-to-report-first-quarter-2026-financial-results-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-to-report-first-quarter-2026-financial-results-on-may-6-2026</guid>
<pubDate>Fri, 24 Apr 2026 12:33:00 GMT</pubDate>
<description>BILLERICA, Mass., April 24, 2026--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results.</description>
</item>
<item>
<title>Quanterix Debuts Content Innovation Engine at AACR 2026</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-debuts-content-innovation-engine-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-debuts-content-innovation-engine-at-aacr-2026</guid>
<pubDate>Wed, 15 Apr 2026 12:33:00 GMT</pubDate>
<description>BILLERICA, Mass., April 15, 2026--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration of Akoya Biosciences' spatial biology platform and Quanterix's decades of ultra-sensitive, quantitative immunoassay development from the SIMOA® technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a syste</description>
</item>
<item>
<title>Quanterix Corporation Announces Date of 2026 Annual Meeting</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-corporation-announces-date-of-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-corporation-announces-date-of-2026-annual-meeting</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection</description>
</item>
<item>
<title>Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-releases-financial-results-for-the-fourth-quarter-and-full-year-2025</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-releases-financial-results-for-the-fourth-quarter-and-full-year-2025</guid>
<pubDate>Mon, 02 Mar 2026 21:01:00 GMT</pubDate>
<description>BILLERICA, Mass., March 02, 2026--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide</title>
<link>https://6ix.com/company/quanterix-corp/news/lucent-diagnostics-and-life-line-screening-partner-to-bring-advanced-blood-based-diagnostics-to-communities-nationwide</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/lucent-diagnostics-and-life-line-screening-partner-to-bring-advanced-blood-based-diagnostics-to-communities-nationwide</guid>
<pubDate>Mon, 02 Mar 2026 13:33:00 GMT</pubDate>
<description>BILLERICA, Mass., March 02, 2026--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent’s non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the goa</description>
</item>
<item>
<title>Quanterix to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Thu, 26 Feb 2026 13:33:00 GMT</pubDate>
<description>BILLERICA, Mass., February 26, 2026--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March:</description>
</item>
<item>
<title>Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-2-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-2-2026</guid>
<pubDate>Fri, 20 Feb 2026 13:33:00 GMT</pubDate>
<description>BILLERICA, Mass., February 20, 2026--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results.</description>
</item>
<item>
<title>Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-announces-fda-510-k-133300606</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-announces-fda-510-k-133300606</guid>
<pubDate>Tue, 03 Feb 2026 13:33:00 GMT</pubDate>
<description>BILLERICA, Mass., February 03, 2026--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer’s disease (AD). This submission represents a significant milestone in the Company’s mission to provide superior, non-invasive, high-performance diagnos</description>
</item>
<item>
<title>Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-announces-landmark-jama-study-133300863</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-announces-landmark-jama-study-133300863</guid>
<pubDate>Wed, 21 Jan 2026 13:33:00 GMT</pubDate>
<description>BILLERICA, Mass., January 21, 2026--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the high impact journal JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842215. The study, led by researchers at Amsterdam UMC, followed a cohort of nearly 300 individuals for up to 15 years. The findings demonstrated that while individu</description>
</item>
<item>
<title>Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-corporation-reports-inducement-grants-210100775</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-corporation-reports-inducement-grants-210100775</guid>
<pubDate>Fri, 16 Jan 2026 21:01:00 GMT</pubDate>
<description>BILLERICA, Mass., January 16, 2026--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026, inducement grants (the "Inducement Grants") were made to four employees in connection with the commencement of their employment. The Inducement Grants consist of 88,050 restricted stock units ("RSUs") representing 88,050 shares of Quanterix common</description>
</item>
<item>
<title>Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-appoints-everett-cunningham-president-213000466</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-appoints-everett-cunningham-president-213000466</guid>
<pubDate>Thu, 08 Jan 2026 21:30:00 GMT</pubDate>
<description>BILLERICA, Mass., January 08, 2026--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company’s next President and Chief Executive Officer and a member of the Board, effective January 19, 2026.</description>
</item>
<item>
<title>Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-announces-landmark-nature-study-123000222</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-announces-landmark-nature-study-123000222</guid>
<pubDate>Mon, 22 Dec 2025 12:30:00 GMT</pubDate>
<description>BILLERICA, Mass., December 22, 2025--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The study, which utilized Quanterix’s ultra-sensitive Simoa p-Tau 217 (phosphorylated tau at threonine 217) research assay, is the largest population-based assessment of Alzheimer’s Disease Neuropathological Changes (ADNC) to date, provi</description>
</item>
<item>
<title>Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-announces-board-leadership-changes-211500545</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-announces-board-leadership-changes-211500545</guid>
<pubDate>Thu, 20 Nov 2025 21:15:00 GMT</pubDate>
<description>BILLERICA, Mass., November 20, 2025--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company’s next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company’s Board</description>
</item>
<item>
<title>Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-announces-landmark-study-demonstrating-223000295</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-announces-landmark-study-demonstrating-223000295</guid>
<pubDate>Mon, 17 Nov 2025 22:30:00 GMT</pubDate>
<description>BILLERICA, Mass., November 17, 2025--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the publication of a landmark study in the high-impact journal Brain. The paper validates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) establish a robust, complementary two-pronged approach for comprehensive Multiple Sclerosis (MS) disease</description>
</item>
<item>
<title>Quanterix Releases Financial Results for the Third Quarter of 2025</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-releases-financial-results-third-210100436</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-releases-financial-results-third-210100436</guid>
<pubDate>Mon, 10 Nov 2025 21:01:00 GMT</pubDate>
<description>BILLERICA, Mass., November 10, 2025--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-report-third-quarter-2025-120000822</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-report-third-quarter-2025-120000822</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>BILLERICA, Mass., November 03, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m. E.T., to discuss its third quarter 2025 financial results.</description>
</item>
<item>
<title>Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-accelerator-laboratory-awarded-rigorous-203000108</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-accelerator-laboratory-awarded-rigorous-203000108</guid>
<pubDate>Thu, 21 Aug 2025 20:30:00 GMT</pubDate>
<description>BILLERICA, Mass., August 21, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanteri</description>
</item>
<item>
<title>Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-present-canaccord-genuity-45th-110000640</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-present-canaccord-genuity-45th-110000640</guid>
<pubDate>Mon, 11 Aug 2025 11:00:00 GMT</pubDate>
<description>BILLERICA, Mass., August 11, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadership team will present at the Canaccord Genuity 45th Annual Growth Conference in Boston, Massachusetts on Tuesday, August 12th, at 3:30 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference.</description>
</item>
<item>
<title>Quanterix Releases Financial Results for the Second Quarter of 2025</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-releases-financial-results-second-200600409</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-releases-financial-results-second-200600409</guid>
<pubDate>Thu, 07 Aug 2025 20:06:00 GMT</pubDate>
<description>BILLERICA, Mass., August 07, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/quanterix-corp/news/quanterix-report-second-quarter-2025-200200254</link>
<guid isPermaLink="true">https://6ix.com/company/quanterix-corp/news/quanterix-report-second-quarter-2025-200200254</guid>
<pubDate>Mon, 04 Aug 2025 20:02:00 GMT</pubDate>
<description>BILLERICA, Mass., August 04, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 7, 2025, at 4:30 p.m. E.T., to discuss its second quarter 2025 financial results.</description>
</item>
</channel>
</rss>